autoimmune disease

Creating Disease Severity and Quality-of-Life Scoring Systems for Blistering Diseases

March 2025

Comparing the efficacy of existing therapies between clinical trials, as well as evaluating new treatments, requires an accurate and reliable assessment of the clinical nature of a disease. Yet the first comprehensive analysis of the interventions used to treat pemphigus, a range of autoimmune blistering diseases (AIBD), was inconclusive due to incomplete information, including absence…

JAK Inhibitor Therapy for Alopecia Areata

December 2023

Dr. Aguh presented about alopecia areata (AA) and treatment with JAK inhibitors. First, Dr. Aguh described AA and the categories of disease severity. Common subtypes of AA include patch, totalis, and universalis; additional subtypes include ophiasis, incognito, and canitis subita, which manifests as sudden graying of the hair. She described that fortunately, most patients have…

Off to the Races: Engineering CA(A)R-T Cells for Skin Disease Therapy

August 2023

CAR T cell therapy is a personalized immunotherapy technology. A patient’s T cells are collected, genetically altered to express chimeric antigen receptors, and reinfused. CAR T cells seek out and kill target cells that express the specified antigen, such as CD19 or B cell maturation antigen (BCMA). Additionally, CAR T cells are programmed to proliferate and produce memory CAR T cells in the presence of target cells. Ongoing research into chimeric antigen receptor (CAR) T cell therapy and chimeric autoantibody receptor (CAAR) T cell therapy for cancers and autoimmune diseases, including pemphigus vulgaris (PV) may lead to clinical trials.

Topics